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Aim To investigate the association of nephrolithiasis and 
solute carrier family 2, facilitated glucose transporter, 
member 9 (SLC2A9), also known as glucose transporter 
type 9, Glut9.
Methods A total of 145 participants were recruited in the 
period April-October 2008 from the Department of Miner-
al Research of the Medical School Osijek, Osijek, Croatia; 58 
(40%) had confirmed nephrolithiasis and 87 (60%) were as-
ymptomatic. Four single nucleotide polymorphisms (SNP) 
from the SLC2A9 gene were genotyped in both groups 
(rs733175, rs6449213, rs1014290, and rs737267).
Results There was a weak but significant association of all 
4 SNPs and nephrolithiasis (P = 0.029 for rs733175; P = 0.006 
for rs6449213; P = 0.020 for rs1014290, and P = 0.011 for 
rs737267). Logistic regression in an age- and sex-adjusted 
model suggested that genotype C/T for rs6449213 had 
odds ratio for nephrolithiasis of 2.89 (95% confidence inter-
val 1.13-7.40). This SNP explained a total of 4.4% of neph-
rolithiasis variance.
Conclusion Development of nephrolithiasis may be as-
sociated with SLC2A9 gene. Further studies are needed to 
clarify the role of SLC2A9 gene as a link between uric acid 
and nephrolithiasis.
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Renal stone formation (nephrolithiasis) is a disease charac-
terized by the existence of solid deposits in the upper parts 
of the urinary tract (1). It is estimated to affect between 
3%-9% of the population, with large differences between 
various populations (2,3). There is a number of causes that 
may lead to the renal stones formation, including diet and 
obesity status, some drugs, other diseases, climate chang-
es, metabolic disorders, and genetic factors (2,4,5). The 
complexity of this disease caused researchers to consider 
nephrolithiasis as one feature of a broader systemic dis-
ease, rather than a local disease restricted to a single or-
ganic system (6). This is especially interesting in relation to 
gout and metabolic syndrome, which are both systemic 
disorders in close relation to nephrolithiasis (6-8). Even the 
cohort studies have confirmed the association of gout and 
kidney stones, suggesting that the history of gout increas-
es the risk for kidney stones (9). Another study showed 
that, in the age-adjusted model, gout had an odds ratio of 
1.97 for previous kidney stones (95% confidence interval 
[CI], 1.37-2.83) and that even after adjustment for sex, race, 
body mass index, and presence of hypertension the odds 
ratio remained significant (10).
Genetic contribution to renal stones formation has been 
identified long time ago (2). In line with these suggestions, 
heritability of some of the traits associated with nephroli-
thiasis has been shown to be as high as 95% (11). Herita-
bility of the urinary stones was reported to be lower (56%) 
(12), but still sufficiently high to be considered a substan-
tial genetic proportion of variance and suggesting that it 
may be under genetic control. So far, a number of stud-
ies have established a link between predominantly oxa-
late kidney stones and several genes, including vitamin-D 
receptor gene (VDR) and calcitonin receptor (CTR) gene 
(13), heparan sulfate (HSPG2) gene (14), or fibronectin 
gene (FN1) (14).
The quantitative trait associated with nephrolithiasis is the 
serum uric acid concentration, which is under strong ge-
netic control by the gene for glucose transporter type 9 
(SLC2A9 or Glut 9) (15). The gene was initially described 
in an isolated island community (16,17), where genetic 
properties of the population are expected to act in fa-
vor of facilitated gene mapping efforts (18). Subsequent 
meta-analysis of 14 populations confirmed the associa-
tion of this gene with serum uric acid concentrations (19). 
This led to a number of clinical studies that have con-
firmed its involvement in the uric acid metabolism, in-
cluding urate handling in the kidney and uptake in the 
liver (20,21). Based on the previous suggestions that gout 
and nephrolithiasis may share a common pathway (15), 
it might be interesting to see if SLC2A9 could explain the 
commonalities in patients with any of the following con-
ditions. Therefore, the aim of this study was to investigate 
the association of nephrolithiasis and genetic variants of 
the SLC2A9.
PARTIcIPAnTS AnD MeThODS
We investigated 145 patients from the Department of 
Mineral Research of the Medical School Osijek, Osijek, Cro-
atia. The sampling was based on the hospital nephrolithia-
sis register with over 2000 entries since 1988, but only pa-
tients with confirmed urate nephrolithiasis were included 
in the sampling frame. After identification, a postal invita-
tion was sent to all eligible patients (over a hundred of 
participants), 58 of which responded and were included 
in the study. The diagnosis of nephrolithiasis was based 
on the history of renal colic, with confirmed hematuria 
and voiding of the calculus or previous surgical and en-
doscopic removal of stone(s), or radiographic evidence of 
stone(s), and the report of stone analysis (3,5). The partici-
pants were invited and their samples were collected from 
April-October 2008. Further 87 patients who were un-
dergoing osteoporosis diagnostics and had no recorded 
symptom associated with nephrolithiasis were recruited 
from the same department by the consecutive sampling 
in April-October 2008. The following participants were 
excluded: participants with gout, gastro-intestinal dis-
eases (ulcerative colitis, malabsorption syndrome, chron-
ic pancreatitis), renal tubular acidosis, pregnant women, 
participants over 75 years, participants with primary hy-
perparathyroidism and other diseases affecting calcium 
metabolism (hyperthyroidism, acromegaly, sarcoidosis, 
diabetes, or cancer), and participants using drugs such as 
corticosteroids, barbiturates, estrogen, or vitamin D. Writ-
ten consent was obtained from all participants and the 
study was approved by the Ethics Committee of the Medi-
cal School Osijek, Osijek, Croatia.
We performed genotyping for both groups, including 4 
single nucleotide polymorphisms (SNP) from the SLC2A9 
gene: rs733175, rs6449213, rs1014290, and rs737267. The 
selection of these 4 SNPs was based on the results from a 
previous study, which suggested that these SNPs showed 
the strongest association with uric acid concentration 
(15). These SNPs have different locations within a gene: 
rs733175 is located at 5’ end, rs6449213 within intron 
4, rs1014290 within intron 3, and rs737267 within in-
tron 7, all on the chromosome 4 within the region 
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4p16.1 (9,260-9960 kb) (15). All SNPs were genotyped us-
ing TaqMan SNP Genotyping assays and fluorescence was 
performed using an ABI 7000 sequence detection system 
(Applied Biosystems, Foster City, CA, USA). Genotyping pro-
cedures were performed according to the manufacturer’s 
protocols, except for the PCR amplifications, which were 
carried out in half of the original volume, with all reagents 
volumes adjusted accordingly (22). Genotyping proce-
dures were performed in the DNA laboratory of the J. J. 
Strossmayer University of Osijek, School of Medicine.
Statistical analysis
The data were analyzed as the proportions of the geno-
types in each group. Due to the small number of partici-
pants, Fisher exact test was used, performed by the inter-
net-based Simple Interactive Statistical Analysis (23), using 
the 2 × 5 Fisher exact test option. This is a generalization 
of the Fisher exact test, which calculates an exact prob-
ability value for the relationship between more variables, 
based on the two loops analysis, one for each degree of 
freedom (23). Additionally, descriptive statistics for numeri-
cal variables and the calculation of Mann-Whitney test and 
logistic regression were performed using R package (The R 
Project for Statistical Computing, version 2.10.1, Bell Labo-
ratories, NJ, USA; available from http://www.r-project.org/). 
Level of significance was set at P < 0.05.
ReSuLTS
A total of 145 participants were included in this study: 58 
(40%) had symptoms of nephrolithiasis and 87 (60%) had 
no symptoms of nephrolithiasis and were thus considered 
asymptomatic. The symptomatic participants were older, 
less likely to be women, and had significantly greater body 
mass index and waist circumference (Table 1).
The SNP analysis indicated significant differences among 
symptomatic and asymptomatic participants in all 4 SNPs, 
with the largest difference for rs6449213 (Table 2). Since 
the sample size was rather small for a detailed analysis, 
only this SNP was included in the logistic regression mod-
el, which was adjusted for the effects of age and sex. Odds 
ratio for being heterozygous at this SNP and developing 
nephrolithiasis was 2.89 (95% CI, 1.13-7.14) (Table 3). The 
entire model with all 3 variables explained a total of 31.2% 
of variance, while the rs6449213 explained 4.4% of total 
nephrolithiasis variance.
TAbLe 2. Genotype frequencies (percentages) in symptomatic 
and asymptomatic participants included in the present study
Marker/
status
Symptomatic 
participants
Asymptomatic 
participants Total P*
rs733175
TT 30 (51.7) 50 (57.5) 80 (55.2) 0.029
CT 24 (41.4) 33 (37.9) 57 (39.3)
CC  4 (6.9)  4 (4.6)  8 (5.5)
rs6449213
TT 30 (51.7) 57 (65.5) 87 (60.0) 0.006
CT 25 (43.1) 24 (27.6) 49 (33.8)
CC  3 (5.2)  6 (6.9)  9 (6.2)
rs1014290
TT 27 (46.6) 47 (54.0) 74 (51.0) 0.020
CT 25 (43.1) 31 (35.6) 56 (38.6)
CC  6 (10.3)  9 (10.3) 15 (10.3)
rs737267
GG 28 (48.3) 51 (58.6) 79 (54.5) 0.011
GT 26 (44.8) 28 (32.2) 54 (37.2)
TT  4 (6.9)  8 (9.2) 12 (8.3)
*Fisher exact test.
TAbLe 3. The association of nephrolithiasis and SnP rs6449213, 
age, and sex, in a logistic regression model
Variable
Odds ratio 
(95% confidence interval) P
Age 1.04 (0.99-1.09)  0.108
Sex:
men (Ref.) 1.00 <0.001
women 0.20 (0.08-0.45)
SnP rs6449213
TT (Ref.) 1.00
CT 2.89 (1.13-7.40)  0.026
CC 1.71 (0.20-15.01)  0.628
TAbLe 1. basic characteristics of nephrolithiasis in symptomatic and asymptomatic participants included in the present study
characteristics
Symptomatic participants 
(n = 58)
Asymptomatic participants 
(n = 87) P
Age; median (interquartile range)  58.5 (18.0) 53.0 (9.0)  0.002*
Women; n (%)  15 (28.8) 61 (75.3) <0.001†
Body mass index; median (interquartile range)  29.2 (5.2) 26.6 (5.9) <0.001*
Waist circumference; median (interquartile range) 105.5 (17.0) 87.0 (19.0) <0.001*
*Mann-Whitney test.
†χ2 test.
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DIScuSSIOn
This study suggests the association between the SLC2A9 
gene and nephrolithiasis, indicating that the SLC2A9 could 
be the common pathway that links nephrolithiasis and 
gout (10). Furthermore, the same gene was previously as-
sociated with metabolic syndrome (15), thus offering a 
possible explanation of the link between the 3 disorders. 
Interestingly, the population in which the gene was origi-
nally described has a very high reported prevalence of 
metabolic syndrome (24), lipid disorders (25), and also in-
creased odds for hypertension (18,26-28), indicating a pos-
sible link and the complexity among all these factors and 
diseases. Also, isolated populations usually have increased 
odds for nephrolithiasis (29), due to population dynamics 
and increased prevalence of consanguineous marriages 
(18,30-33).
The results of our study have to be considered in the 
light of several serious limitations. The first is the use of 
heterogeneous and small sample size, especially in com-
parison with recent genetic studies that have analyzed 
thousands of samples (34,35). Furthermore, the selec-
tion of asymptomatic participants in this study could be 
the source of bias, which was at least partly overcome 
by the multivariate analysis method used in the last step 
of the analysis. The result that suggests that heterozy-
gous individuals have higher odds ratios for developing 
nephrolithiasis is unusual, especially as the odds ratio of 
recessive homozygotes was lower than that of heterozy-
gotes. A possible explanation could be that the sample 
composition could have favored such a result. In turn, 
this suggests that replication studies will be needed in 
order to firmly establish the nature of association of this 
gene with nephrolithiasis. The study also suffers from 
minimalistic and over-simplistic attempt to explain such 
a complex phenomenon as the nephrolithiasis by inves-
tigating just a set of several variables and ignoring the 
large number of described confounders. One such con-
founder is the type of renal excrement, which is often 
of mixed type, additionally suggesting the complexity of 
this end-phenotype in humans. The data for this study 
also did not include sufficient information on metabolic 
syndrome diagnosing, not allowing us to compare neph-
rolithiasis status with this disorder and further investigate 
the link between nephrolithiasis and other metabolic 
disruptions. Lastly, it might be very interesting to see if 
the symptomatic individuals were urate stone formers, 
but this and some other biochemical parameters, were 
unavailable in this study.
Despite its limitations, this study is, to the best of our 
knowledge, one of the first studies demonstrating the 
possible association of SLC2A9 and nephrolithiasis, thus 
offering a potential for further genetic investigation into 
the development of nephrolithiasis. It must be noted that 
the causes for nephrolithiasis are numerous (2) and that SL-
C2A9 is likely involved in just a fraction of the total variance 
of the stones formation. To further elucidate the possible 
linkage of SLC2A9 and nephrolithiasis, it would be needed 
to repeat this type of study on a much larger sample with 
detailed clinical history. This would enable the calculation 
of the percent of nephrolithiasis variance that could be at-
tributed to SLC2A9. Additionally, it might be interesting to 
perform an intervention study on the patients with known 
genotypes, aiming to show the changes in the dynamics of 
urinary excretion associated with mutations of the SLC2A9 
gene. Such a study could explain if there are indeed subtle 
changes in the excretion pattern, which could over time 
contribute to the development of the nephrolithiasis.
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